BTAIQ(BioXcel Therapeutics, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|
| 营业收入 | $375.00K | $1.38M | $2.27M | $642.00K |
| 毛利润 | $355.00K | $120.00K | $123.00K | $478.00K |
| 营业利润 | −$159.65M | −$171.78M | −$67.25M | −$50.46M |
| 净利润 | −$165.76M | −$179.05M | −$59.60M | −$69.90M |
| 经营现金流 | −$135.34M | −$155.01M | −$72.03M | −$57.62M |
| 自由现金流 | −$135.48M | −$155.03M | −$72.03M | −$57.62M |
| 摊薄每股收益 | $-94.72 | $-98.33 | $-23.51 | $-5.73 |